Magnesium alginate reduces GER symptoms in both formula-fed and breast-fed infants

  • Baldassarre ME & al.
  • Int J Environ Res Public Health
  • 20 Dec 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Infants with gastroesophageal reflux (GER) symptoms can benefit from magnesium-alginate treatment if they do not respond to behavioral and dietary changes.

Why this matters

  • Infant regurgitation is the most common functional gastrointestinal disorder in children aged

Study design

  • Researchers in this multicenter prospective crossover trial studied formula-fed infants with persistent regurgitation, randomly assigning them to receive either 2 weeks of a magnesium-alginate-based supplement followed by 2 weeks of thickened formula (n=27; mean age, 51.8±41.1 days) or thickened formula followed by magnesium alginate (n=26; mean age, 84.4±57.2 days).
  • They also followed a third group of exclusively breast-fed infants receiving magnesium alginate for up to 2 weeks (n=19; mean age, 60.6±29.6 days).
  • They evaluated symptoms using the Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R) and calculated direct treatment costs.
  • Funding: Study products were supplied by Aurora Biofarma.

Key results

  • I-GERQ-R scores lowered significantly in both formula-fed groups (F=55.387; P<.001 regardless of administration sequence effect: f="0.268;" p=".848).</span">
  • Magnesium alginate was as effective in breast-fed infants (t=1.55; P=.126).
  • Mean cost savings were significant with magnesium alginate at €4.60±11.2 per formula-fed infant (t=2.91; P<.0005>

Limitations

  • The sample was small, and follow-up was short.